RhumbLine Advisers’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-63,319
| Closed | -$829K | – | 4099 |
|
|
2025
Q4 | $829K | Sell |
63,319
-5,806
| -8% | -$69.3K | ﹤0.01% | 2339 |
|
|
2025
Q3 | $503K | Sell |
69,125
-6,549
| -9% | -$44.3K | ﹤0.01% | 2698 |
|
|
2025
Q2 | $406K | Buy |
75,674
+11,663
| +18% | +$56.5K | ﹤0.01% | 2814 |
|
|
2025
Q1 | $342K | Buy |
64,011
+1,848
| +3% | +$12.9K | ﹤0.01% | 2814 |
|
|
2024
Q4 | $556K | Buy |
62,163
+1,381
| +2% | +$14.7K | ﹤0.01% | 2617 |
|
|
2024
Q3 | $669K | Sell |
60,782
-4,593
| -7% | -$51.1K | ﹤0.01% | 2514 |
|
|
2024
Q2 | $595K | Buy |
65,375
+2,556
| +4% | +$25K | ﹤0.01% | 2554 |
|
|
2024
Q1 | $884K | Buy |
62,819
+25,209
| +67% | +$314K | ﹤0.01% | 2320 |
|
|
2023
Q4 | $289K | Buy |
37,610
+5,811
| +18% | +$32.1K | ﹤0.01% | 2997 |
|
|
2023
Q3 | $237K | Buy |
31,799
+1,667
| +6% | +$14.2K | ﹤0.01% | 3061 |
|
|
2023
Q2 | $251K | Buy |
+30,132
| New | +$348K | ﹤0.01% | 3114 |
|
|
2021
Q2 | – | Sell |
-3,524
| Closed | -$61K | – | 2993 |
|
|
2021
Q1 | $61K | Hold |
3,524
| – | – | ﹤0.01% | 2969 |
|
|
2020
Q4 | $45K | Buy |
3,524
+1,261
| +56% | +$22.5K | ﹤0.01% | 3024 |
|
|
2020
Q3 | $84K | Sell |
2,263
-356
| -14% | -$14.1K | ﹤0.01% | 2894 |
|
|
2020
Q2 | $101K | Buy |
+2,619
| New | +$93.3K | ﹤0.01% | 2965 |
|
RhumbLine Advisers's ATXS Position: Q1 2026 in Review
RhumbLine Advisers sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 63,319 shares — an estimated $829K sold.
RhumbLine Advisers first reported a position in ATXS in Q2 2020 and held it in 15 quarters. The position peaked at $884K in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- RhumbLine Advisers reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- RhumbLine Advisers sold 63,319 Astria Therapeutics shares in Q1 2026, an estimated $829K.
- RhumbLine Advisers first reported a position in Astria Therapeutics in Q2 2020 and held it in 15 quarters.
- RhumbLine Advisers's Astria Therapeutics position peaked at $884K in Q1 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.